近日,美国科学家在最新出版的《国际癌症杂志》上刊文指出,对淋巴结阳性的乳腺癌妇女来说,酪氨酸激酶受体c-Met的过度表达与其不良的临床预后相关联,而与Her2/neu的表达无关。来自于美国芝加哥大学的Ernst Lengyel医生告诉路透健康记者说,c-Met将可能作为辅助靶向Her2/neu治疗的新靶标。在40例淋巴结阳性的乳腺癌妇女患者中,研究人员分别对c-Met和Her2/neu在乳腺癌细胞中的表达差异性进行了检测研究。细胞膜染色技术只能 Recently, American scientists recently published in the “International Journal of Cancer,” published an article that for lymph node-positive breast cancer women, tyrosine kinase receptor c-Met overexpression associated with its poor clinical prognosis, and Her2 / neu expression has nothing to do. Ernst Lengyel, MD, from the University of Chicago, told Reuters Health reporters that c-Met may serve as a new target to help target Her2 / neu therapy. In 40 women with lymph node-positive breast cancer, the researchers examined the differences in the expression of c-Met and Her2 / neu in breast cancer cells, respectively. Cell membrane staining technology only